Abstract: Hybridoma cell lines producing monoclonal antibodies specific to the human epidermal growth factor receptor are disclosed. The antibodies are capable of inhibiting the growth of human tumor cells expressing human epidermal growth factor receptors. Therapeutic uses of these monoclonal antibodies by themselves and in combination with anti-neoplastic agents are also disclosed.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
April 17, 2001
Assignee:
Rhone-Poulenc Rorer International (Holdings), Inc.
Inventors:
Joseph Schlessinger, David Givol, Francoise Bellot, Richard Kris, George A. Ricca, Christopher Cheadle, Victoria J. South
Abstract: Methods of inhibiting cell proliferation in a patient suffering from such disorder comprising the use of a styryl-substituted heteroaryl compound wherein the heteroaryl group is a monocyclic ring with 1 or 2 heteroatoms, or a bicyclic ring with 1 to about 4 heteroatoms, said compound optionally substituted or polysubstituted, with the proviso that when said ring is polysubstituted, the substituents do not have a common point of attachment to said ring, and those compounds wherein no substituent on the heteroaryl group is a carboxy group or an ester group, and pharmaceutical compositions comprising such compounds.
Type:
Grant
Filed:
March 17, 1994
Date of Patent:
May 23, 1995
Assignee:
Rhone-Poulenc Rorer International (Holdings) Inc.